Clinical Trial

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Name: NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia — clinical trial record (NCT07105098)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Protocol Amendment History 1 change

notable Trial sites expanded: 11 -> 15 locations 2026-05-16

Trial Details

NCT Number	NCT07105098
Lead Sponsor	Neurocrine Biosciences
Conditions	Schizophrenia
Enrollment	284 participants
Start Date	2025-08-11
Primary Completion	2027-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-05-15